Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments
Open Access
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 298, 202-212
Abstract
No abstract availableKeywords
Funding Information
- Defense Threat Reduction Agency (HDTRA1-12-D-0003-0014)
This publication has 56 references indexed in Scilit:
- Development of Burkholderia mallei and pseudomallei vaccinesFrontiers in Cellular and Infection Microbiology, 2013
- Strategies for Intracellular Survival of Burkholderia pseudomalleiFrontiers in Microbiology, 2011
- Genome wide transcriptome profiling of a murine acute melioidosis model reveals new insights into how Burkholderia pseudomallei overcomes host innate immunityBMC Genomics, 2010
- The BpeAB-OprB Efflux Pump of Burkholderia pseudomallei 1026b Does Not Play a Role in Quorum Sensing, Virulence Factor Production, or Extrusion of Aminoglycosides but Is a Broad-Spectrum Drug Efflux SystemAntimicrobial Agents and Chemotherapy, 2010
- The Treatment of MelioidosisPharmaceuticals, 2010
- Preparation and characterization of niosomes containing ribavirin for liver targetingDrug Delivery, 2010
- Present and future therapeutic strategies for melioidosis and glandersExpert Review of Anti-infective Therapy, 2010
- Enhanced Oral Bioavailability of Griseofulvin via NiosomesAAPS PharmSciTech, 2009
- Melioidosis: Epidemiology, Pathophysiology, and ManagementClinical Microbiology Reviews, 2005
- In Vitro Antibiotic Susceptibilities of Burkholderia mallei (Causative Agent of Glanders) Determined by Broth Microdilution and E-TestAntimicrobial Agents and Chemotherapy, 2001